BillionToOne Inc. Class A Common Stock (BLLN)
Stock · NASDAQ · Health Care
$98.1as of 10/16/2026
Price chart
Active signals
Support level
$95.81
Industry
Medical Specialities
About BLLN
BillionToOne, Inc., a precision diagnostics company, quantifies biology to create molecular diagnostics. The company provides molecular counting platform, which is designed to detect and measure DNA molecules at the single-count level to help enhance disease detection. It also offers UNITY Complete, a non-invasive prenatal screen that assesses fetal risk for aneuploidies, recessive conditions, and fetal antigens from…
- Sector
- Health Care
- Industry
- Medical Specialities
- Employees
- 713
- Website
- www.billiontoone.com/
Fundamentals
- 1-day range
- $96.21$102.57
- Market cap
- $4.22B
- P/E (trailing)
- 128.54
- P/E (forward)
- 66.07
- EPS (trailing)
- $0.77
- Dividend yield
- —
- Beta
- 0.17
- Avg. volume
- 674.0K
52-week range
$61.96$150.44
Next earnings: November 4, 2026 · EPS estimate $0.30confirmed
How BillionToOne Inc. Class A Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 11, 2026 · via SEC EDGAR / Finnhub
Gross Profit$208.46M(68%)
Operating Income$16.02M(5%)
Forecasts
7 analyst ratings
Buy 79%
Hold 21%
Sell 0%
1-year price forecast
High
$145
+47.8%
Median
$130
+32.5%
Low
$110
+12.1%
BillionToOne Inc. Class A Common Stock Competitors
Chosen by industry and closest market cap.
- BLLNBillionToOne Inc. Class A Common Stock$98.12▼ 4.49%Market cap $4.22BP/E 128.54$61.96$150.44
- CONConcentra Group Holdings Parent Inc. Common Stock$38.54▼ 1.56%Market cap $3.91BP/E 24.09$18.55$38.07
- CELCCelcuity Inc. Common Stock$56.58▼ 6.17%Market cap $4.55BP/E —$46.51$151.02
- VCYTVeracyte Inc. Common Stock$43.12▼ 2.86%Market cap $3.71BP/E 31.17$29.46$60.91
- RDNTRadNet Inc. Common Stock$68.8▼ 2.29%Market cap $5.36BP/E —$50.82$85.84
- ACHCAcadia Healthcare Company Inc. Common Stock$29.98▼ 3.41%Market cap $2.86BP/E —$11.43$35.83
- CAICaris Life Sciences Inc. Common Stock$30.56▼ 3.78%Market cap $5.65BP/E 76.07$14.19$33.66
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| BLLN BillionToOne Inc. Class A Common Stock | $4.22B | 128.54 | $98.12 | ▼ 4.49% | $61.96$150.44 |
| CON Concentra Group Holdings Parent Inc. Common Stock | $3.91B | 24.09 | $38.54 | ▼ 1.56% | $18.55$38.07 |
| CELC Celcuity Inc. Common Stock | $4.55B | — | $56.58 | ▼ 6.17% | $46.51$151.02 |
| VCYT Veracyte Inc. Common Stock | $3.71B | 31.17 | $43.12 | ▼ 2.86% | $29.46$60.91 |
| RDNT RadNet Inc. Common Stock | $5.36B | — | $68.8 | ▼ 2.29% | $50.82$85.84 |
| ACHC Acadia Healthcare Company Inc. Common Stock | $2.86B | — | $29.98 | ▼ 3.41% | $11.43$35.83 |
| CAI Caris Life Sciences Inc. Common Stock | $5.65B | 76.07 | $30.56 | ▼ 3.78% | $14.19$33.66 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Natera: Priced To Perfection Amidst Rising Competitive ThreatsSeekingAlpha · 10/7/2026
- BillionToOne’s Tissue-Free Northstar Response® Demonstrates On-Par to Superior Cancer Treatment Monitoring vs. Tumor-Informed Assay, New Peer-Reviewed Study FindsYahoo · 10/7/2026
- BillionToOne (NasdaqGS:BLLN) Stock Fair Value Edges Higher As Analysts Weigh Tech And Reimbursement RiskYahoo · 10/3/2026
- Guggenheim Maintains Buy on BillionToOne, Raises Price Target to $128Benzinga · 10/1/2026
- BillionToOne (BLLN) Stock Could Be A Bargain As It Jumps 30% YTDYahoo · 9/23/2026
- Medicare Lab Fee Changes Impact BillionToOne, CareDx DifferentlyBenzinga · 9/23/2026
- BillionToOne Stock Jumped 12% Yesterday. Here’s What the Streets Target.Yahoo · 9/23/2026
- BillionToOne SVP Sells 1,416 SharesYahoo · 9/21/2026
Insider Activity
Insider Actions →Acquired
13.3K
Disposed
24.8K
- Tsao David · October 5, 2026 · Option Exercise10.0K @ $2.8
- Tsao David · October 5, 2026 · Sale100 @ $110.09
- Tsao David · October 5, 2026 · Sale1.8K @ $109.14
- Tsao David · October 5, 2026 · Sale4.9K @ $108.53
- Tsao David · October 5, 2026 · Sale2.2K @ $107.47
- Tsao David · October 5, 2026 · Sale400 @ $106.1
- Tsao David · October 5, 2026 · Sale555 @ $105.56
- Tsao David · October 5, 2026 · Sale20 @ $110.08
- Tsao David · October 5, 2026 · Sale2.9K @ $109
- Tsao David · October 5, 2026 · Sale4.3K @ $108.39
- Tsao David · October 5, 2026 · Sale1.9K @ $107.2
- Tsao David · October 5, 2026 · Sale866 @ $105.9
- ten Bosch John Roderick · October 5, 2026 · Sale1.4K @ $105.15
- Tsao David · September 24, 2026 · Option Exercise3.3K @ $2.8
- Tsao David · September 24, 2026 · Sale3.3K @ $125
Institutional Ownership
March 31, 2026
- Total shares held
- 10.94M
- Total value held
- $784.60M
- Institutional holders
- 86
Top holders this quarter
- Unknown1.71M
- Unknown1.26M
- Unknown1.10M
- Unknown741.5K
- Unknown737.5K
- Unknown709.2K
- Unknown513.3K
- Unknown406.5K
- Unknown369.6K
- Unknown240.6K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 8, 2026
BLLN Gets Price Target Hike and New Study Data
BillionToOne reported that its Northstar Response test showed results comparable to or better than tumor-informed assays in a new peer-reviewed study. Guggenheim raised its price target to $128, while other analysts noted rising reimbursement risks. The stock is currently trading near its support level of $95.81.
BLLN Gets Price Target Hike and New Study Data. BillionToOne reported that its Northstar Response test showed results comparable to or better than tumor-informed assays in a new peer-reviewed study. Guggenheim raised its price target to $128, while other analysts noted rising reimbursement risks. The stock is currently trading near its support level of $95.81.